The difference between REPATHA and placebo in mean percent change in LDL-C from baseline to Week 12 was 31% (95% CI: 44%, 18%
Part of that drop is straightforward physics: a smaller body burns fewer calories simply because there is less tissue to maintain

The three-phase constipation pattern: acute, adaptation, and resolution Based on patterns across published trials and clinical observation, GLP-1 constipation follows a predictable three-phase trajectory in most patients: Phase 1: Acute onset (weeks 1-4) Constipation begins 7-14 days after starting Ozempic or escalating dose Bowel movement frequency drops from baseline (e.g., daily to every 2-3 days) Stool becomes harder and requires more straining Bloating and abdominal fullness are common Patients often mistake this for "the medication working" because fullness overlaps with satiety Phase 2: Adaptation (weeks 4-12) The colon begins compensating for slowed GLP-1-mediated motility Bowel movement frequency stabilizes (not back to baseline but consistent) Stool consistency improves slightly Symptoms plateau rather than worsen Patients who add fiber or osmotic laxatives during this phase see the most benefit Phase 3: Resolution or persistence (week 12+) 60-70% of patients return to near-baseline bowel habits 15-20% have mild persistent constipation that's manageable with dietary changes 10-15% have moderate to severe persistent constipation requiring ongoing laxative use A small subset (2-3%) cannot tolerate the constipation and discontinue treatment The key clinical decision point is week 12

The strongest suppliers are building around familiar formats instead of trying to invent a completely new eating occasion
The microdosing tirzepatide chart provides unit calculations for these non-standard doses
Sleep quality may decrease slightly as enhanced GH signaling fades, though this usually manifests as returning to your pre-protocol baseline rather than becoming worse than before